Linker Information
General Information of This Linker
| Linker ID |
LIN0GIPCV
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Acid-labile linker
|
|||||
| Linker Type |
Unclear
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C10H15N3O3
|
|||||
| Isosmiles |
NNC(CCCCCN1C(C=CC1=O)=O)=O
|
|||||
| InChI |
InChI=1S/C10H15N3O3/c11-12-8(14)4-2-1-3-7-13-9(15)5-6-10(13)16/h5-6H,1-4,7,11H2,(H,12,14)
|
|||||
| InChIKey |
FYWVFGAAKATOHN-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
225.248
|
Polar area
|
92.5
|
||
|
Complexity
|
286
|
xlogp Value
|
-0.5383
|
|||
|
Heavy Count
|
16
|
Rot Bonds
|
6
|
|||
|
Hbond acc
|
4
|
Hbond Donor
|
2
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
SGN-15 [Phase 2 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have histologically confirmed metastatic/unresectable recurrent breast carcinoma with ≤2 prior chemotherapy regimens for metastatic disease or recurrence within 6 months post-adjuvant therapy, measurable disease/bone markers (2×ULN) with Lewis-y antigen expression, and no active brain metastases.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00028483 | Clinical Status | PHASE2 | ||
| Clinical Description |
A Phase II Study Using SGN-15 (cBR96 - Doxorubicin Immunoconjugate) in Combination With Taxotere for the Treatment of Metastatic or Recurrent Breast Carcinoma
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
The study included patients with metastatic or recurrent NSCLC who failed 1-2 prior therapies or recurred within 6 months post-adjuvant chemo, requiring Lewis-y antigen expression and measurable/evaluable disease with ECOG ≤2 and ≥3-month life expectancy, excluding those with prior docetaxel, high anthracycline exposure, active infections, uncontrolled comorbidities, or CNS metastases.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00051571 | Clinical Status | PHASE2 | ||
| Clinical Description |
A Phase II Study Using SGN-15 (cBR96-Doxorubicin Immunoconjugate) in Combination With Docetaxel for the Treatment of Advanced Stage or Recurrent Non-Small Cell Lung Carcinoma
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Patients Enrolled |
Eligible patients had pathologically confirmed stage IIIB/IV NSCLC with ≥1 measurable lesion, no prior metastatic chemotherapy, ECOG ≤2, available tumor block for LeY antigen testing, approved FDG-PET, and adequate organ function, excluding candidates for curative combined therapy.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00086333 | Clinical Status | PHASE2 | ||
| Clinical Description |
A Phase II Study Using FDG-PET to Investigate the Dosing Schedule and Response of Combination SGN-15 (cBR96-Doxorubicin Immunoconjugate) and Docetaxel in Patients With Stage IV or Stage IIIB Non-Small Cell Lung Carcinoma Ineligible for Combined Modality Treatment With Curative Intent
|
||||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Patients Enrolled |
Eligible patients had pathologically confirmed advanced/recurrent ovarian cancer with 2-3 prior therapy failures, ≥20% Lewis-y antigen expression, LVEF>50%, and platinum resistance (progression during/first 6 months post-treatment).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00051584 | Clinical Status | PHASE2 | ||
| Clinical Description |
A Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Gemzar® Versus Single-Agent Gemzar® in Patients With Advanced Ovarian Cancer
|
||||
| Experiment 5 Reporting the Activity Date of This ADC | [5] | ||||
| Patients Enrolled |
Eligible patients had hormone-refractory prostate cancer with disease progression evidenced by tumor growth or rising PSA with metastatic disease, plus documented Lewis (Y) antigen expression via immunohistochemistry on tumor samples.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00031187 | Clinical Status | PHASE2 | ||
| Clinical Description |
Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Taxotere in Patients With Hormone Refractory Prostate Carcinoma
|
||||
References